NOD
Signaling Pathway Map
Research Area
Inhibitory Selectivity
NOD Products
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S2863 |
ML130 (Nodinitib-1)ML130 (Nodinitib-1) is a potent and selective inhibitor of NOD1 with IC50 of 0.56 μM, inhibits NF-κB activation, exhibits 36-fold selectivity over NOD2. |
(E) Gentamicin protection assay performed as in (B) with healthy control MDM (n=4). Quantification of S. typhimurium-CFU after inhibition of NOD1 with ML-130 and MDP pre-stimulation. |
|
| S0004New |
NOD-IN-1NOD-IN-1 (MDK19922, Compound 4) is a potent mixed inhibitor of nucleotide-binding oligomerization domain (NOD)-like receptor 1 (NOD1) and NOD2 with IC50 of 5.74 μM and 6.45 μM, respectively. |
||
| S0349New |
Inarigivir soproxilInarigivir soproxil (GS 9992, SB 9200) is an oral agonist of innate immunity that is believed to act via the activation of the RIG-I and NOD2 pathways. Inarigivir soproxil has broad-spectrum antiviral activity against RNA viruses with EC50 of 2.2 μM and 1.0 μM for HCV 1a and HCV 1b. |
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S2863 |
ML130 (Nodinitib-1)ML130 (Nodinitib-1) is a potent and selective inhibitor of NOD1 with IC50 of 0.56 μM, inhibits NF-κB activation, exhibits 36-fold selectivity over NOD2. |
(E) Gentamicin protection assay performed as in (B) with healthy control MDM (n=4). Quantification of S. typhimurium-CFU after inhibition of NOD1 with ML-130 and MDP pre-stimulation. |
|
| S0004New |
NOD-IN-1NOD-IN-1 (MDK19922, Compound 4) is a potent mixed inhibitor of nucleotide-binding oligomerization domain (NOD)-like receptor 1 (NOD1) and NOD2 with IC50 of 5.74 μM and 6.45 μM, respectively. |
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S0349New |
Inarigivir soproxilInarigivir soproxil (GS 9992, SB 9200) is an oral agonist of innate immunity that is believed to act via the activation of the RIG-I and NOD2 pathways. Inarigivir soproxil has broad-spectrum antiviral activity against RNA viruses with EC50 of 2.2 μM and 1.0 μM for HCV 1a and HCV 1b. |
